Recent Updates
Recently added Catalysts

Breath Test Collection bags

Phase 3

Helicobacter Pylori Infection | Unknown | Infectious Disease |Meridian Bioscience Inc|Last Updated: Dec 20, 2022

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment193

FDA Designations

No designations recorded

Clinical trial landscape

Breath Test Collection bags · 1 trial · 1 indication

Phase 3 1
NCT02010112Bag Mode BreathID Hp Validation Versus Endoscopy in Detection of Helicobacter PyloriHelicobacter Pylori Infection
COMPLETED193 Analytics
PHASE3COMPLETED
Bag Mode BreathID Hp Validation Versus Endoscopy in Detection of Helicobacter Pylori
Helicobacter Pylori InfectionUnlock trial analytics

Study Endpoints

Primary Endpoints

overall percent agreement
21 days

The primary study endpoint is the performance measure (overall percent agreement) in initial diagnosis (presence/ absence of H.pylori) between biopsy results and bag mode breath test.

Secondary Endpoints

overall percent agreement
21 days
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingSINGLE
ModelSINGLE_GROUP
PurposeDIAGNOSTIC

Treatment Arms

ArmTypeDescription
Initial Diagnosis CohortEXPERIMENTALSubjects with clinical indication of H.pylori infection will undergo breath test compared to routine clinical standard of care- endoscopy

Interventions

NameTypeDescription
Breath Test Collection bagsOTHERBreath Collection bags will be used to collect breath of subjects before and after ingestion of 13-C breath test substrate
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites9

Inclusion Criteria: * Present with clinical indication of H. pylori and candidate for upper endoscopy * Have the ability and willingness to sign the Informed Consent Form for initial diagnosis cohort * Naive to treatment in the past 18 months * No known H.pylori status (no conclusive test results w...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Breath Test Collection bags

What is Breath Test Collection bags used for?

Breath Test Collection bags are used for the detection of Helicobacter pylori infection. The device is part of a breath testing system that helps identify the presence of H. pylori, a bacterium associated with gastrointestinal conditions. It is intended for use in diagnostic procedures related to this infection.

Who makes Breath Test Collection bags?

Breath Test Collection bags are developed by Meridian Bioscience Inc, a company traded under the ticker symbol VIVO. The company is responsible for the development and clinical evaluation of this diagnostic product for Helicobacter pylori infection.

What phase is Breath Test Collection bags in?

Breath Test Collection bags are in Phase 3 clinical development. The product is investigational and has completed a Phase 3 trial, but it is not yet approved for commercial use. It remains under evaluation for its diagnostic accuracy in detecting Helicobacter pylori infection.

What clinical trials is Breath Test Collection bags in?

Breath Test Collection bags have one completed Phase 3 trial, NCT02010112, titled 'Bag Mode BreathID Hp Validation Versus Endoscopy in Detection of Helicobacter Pylori'. This trial enrolled 193 participants in the United States and evaluated the device's performance compared to endoscopy for H. pylori detection.

Is Breath Test Collection bags FDA approved?

Breath Test Collection bags are not FDA approved. The product is still in clinical development, having completed a Phase 3 trial. Approval status has not been established, and the device remains investigational for the detection of Helicobacter pylori infection.